Evaluating Photobiomodulation with MTA Pulpotomy for Healing Irreversible Pulpitis in Young Childrens First Permanent Molars

What this Trial Is About

Researchers are evaluating the effectiveness of photobiomodulation PBM, also known as low-level laser therapy, combined with mineral trioxide aggregate MTA pulpotomy for treating irreversible pulpitis in immature first permanent molars of children aged 6 to 9 years. The study compares this combined therapy to MTA pulpotomy alone to see if PBM can enhance healing, reduce inflammation, and manage pain better. This randomized clinical trial includes 72 children divided into two groups to assess clinical and radiographic outcomes over 15 months. Participants are assigned to one of two groups one group receives the standard MTA pulpotomy without photobiomodulation, while the other group receives MTA pulpotomy enhanced with PBM applied to the pulp stumps before placing MTA. PBM uses specific light wavelengths to stimulate pulp regeneration and reduce inflammation. Follow-up visits are scheduled at 3, 6, 12, and 15 months to monitor treatment success and healing progression. During the study, children will undergo clinical exams to check for symptoms such as pain or tenderness, and radiographic imaging to evaluate pulp healing and root development. Researchers will assess the success of the pulpotomy treatment primarily by the absence of clinical symptoms at various intervals. The study also tracks radiographic healing and root growth over 15 months to understand the long-term effects of adding PBM to MTA pulpotomy.

Clinical and Radiographic Assessment of Photobiomodulated MTA Pulpotomy in Immature First Permanent Molars with Irreversible Pulpitis